Savara Inc (NASDAQ:SVRA) Given Average Recommendation of “Moderate Buy” by Analysts

Savara Inc (NASDAQ:SVRA) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $9.86.

SVRA has been the topic of a number of recent research reports. Wells Fargo & Company initiated coverage on Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective on the stock. JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Thursday, December 19th. Evercore ISI restated an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, HC Wainwright dropped their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Savara Trading Down 3.5 %

Shares of SVRA opened at $2.47 on Thursday. The stock’s 50-day moving average is $2.89 and its two-hundred day moving average is $3.51. The stock has a market cap of $423.90 million, a PE ratio of -5.74 and a beta of 0.63. Savara has a 12 month low of $2.44 and a 12 month high of $5.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Insider Transactions at Savara

In related news, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

Several hedge funds and other institutional investors have recently bought and sold shares of SVRA. Vestal Point Capital LP increased its holdings in Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock valued at $33,079,000 after buying an additional 2,685,000 shares during the last quarter. Rosalind Advisors Inc. bought a new stake in Savara in the fourth quarter valued at about $8,151,000. Nantahala Capital Management LLC increased its holdings in Savara by 45.2% in the fourth quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock valued at $23,103,000 after buying an additional 2,344,308 shares during the last quarter. Emerald Advisers LLC bought a new stake in Savara in the fourth quarter valued at about $7,161,000. Finally, Farallon Capital Management LLC increased its holdings in Savara by 49.9% in the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company’s stock valued at $20,983,000 after buying an additional 2,275,000 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.